Dr. Joshua Strauss is featured in Hematology Advisor in Clinician POV section discussing how to Reduce Hypophosphatemia Risk associated with Parenteral Iron Repletion. Read more about key takeaways (View Full Article)
“Overall, hypophosphatemia does not appear to be a class effect for high-dose parenteral iron. Rather, hypophosphatemia appears to be a risk specifically related to the use of ferric carboxymaltose.”
Research by Dr. Strauss focuses on gastrointestinal cancer, and his clinical areas of interest include anemia, hematology, colorectal cancer, gastrointestinal cancer, head and neck cancer, urologic cancer, leukemia, and lymphoma.